Telix to Present at the 2021 Jefferies Virtual Healthcare Conference
June 01, 2021 08:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Chief Executive Officer, Dr. Christian...
Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®
March 30, 2021 18:02 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, March 30, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that it has completed an agreement with...
Czech Republic First European Country to Grant National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product
February 16, 2021 01:05 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that the Ministry of Health of the...
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
September 24, 2020 07:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has submitted a New Drug Application...
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
September 23, 2020 19:30 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has submitted a New Drug Application...
First Patient Dosed in Phase I/II Trial of Renal Cancer Imaging Product in Japan
August 17, 2020 20:00 ET
|
Telix Pharmaceuticals Limited
TOKYO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that...
Telix Japan Signs MOU with ATOX to Use IRE ELiT 68Ge/68Ga-Generator for Phase I Study of Prostate Cancer Diagnostic Imaging
July 27, 2020 02:21 ET
|
Telix Pharmaceuticals Limited
TOKYO, July 27, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce it has...
Telix Pharmaceuticals submits European marketing authorisation application for prostate cancer imaging product
April 30, 2020 20:14 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, May 01, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has submitted a marketing...
Telix Pharmaceuticals to Present at Jefferies Healthcare Conference
June 03, 2019 08:54 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the...
Telix Pharmaceuticals and Emory Winship Cancer Institute to Collaborate on Clinical Trial Using Advanced Imaging of Prostate Cancer for Radiotherapy
May 30, 2019 09:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and ATLANTA, May 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the...